<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485106</url>
  </required_header>
  <id_info>
    <org_study_id>SDS-SAH-001</org_study_id>
    <nct_id>NCT02485106</nct_id>
  </id_info>
  <brief_title>Rifaximin Use in Severe Alcoholic Hepatitis</brief_title>
  <official_title>Effect of Gut Decontamination Using Rifaximin in the Patients With Severe Alcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Vincent's Hospital, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Vincent's Hospital, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to investigate the effect of decontamination by rifaximin in severe&#xD;
      alcoholic hepatitis patients. Patients who take corticosteroid or pentoxifylline will be&#xD;
      randomly allocated to rifaximin group or control group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>6-month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Severe Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Rifaximin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Corticosteroid or Pentoxifylline for 28 days Rifaximin 400mg tid for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Corticosteroid or Pentoxifylline for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>400mg three times per day for 28 days</description>
    <arm_group_label>Rifaximin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid or pentoxifylline</intervention_name>
    <description>Corticosteroid 40mg/day or pentoxifylline 400mg three times per day for 28 days</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Rifaximin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Heavy alcohol drinking within 3 months (Over 40 g/day)&#xD;
&#xD;
          -  Maddrey's discriminant function ≥ 32&#xD;
&#xD;
          -  AST/ALT ration ≥ 2&#xD;
&#xD;
          -  Bilirubin level ≥ 5mg/dL&#xD;
&#xD;
          -  Any one of the following additional criteria : hepatic encephalopathy, enlarged,&#xD;
             tender liver, or peripheral leucocytosis&#xD;
&#xD;
          -  Age : 19-75&#xD;
&#xD;
          -  Jaundice within 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other causes of chronic liver disease (HBV, HCV, or autoimmune hepatitis)&#xD;
&#xD;
          -  Antibiotics or probiotics use within 8 weeks&#xD;
&#xD;
          -  Drug induced hepatotoxicity&#xD;
&#xD;
          -  Acute viral hepatitis (HAV or HEV)&#xD;
&#xD;
          -  Hepatic abscess or cholagitis&#xD;
&#xD;
          -  Hepatocellular carcinoma of modified UICC stage II, III or IV&#xD;
&#xD;
          -  Malignant tumor other than HCC&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Severe chronic extrahepatic disease&#xD;
&#xD;
          -  Type I hepatorenal syndrome&#xD;
&#xD;
          -  Hepatic encephalopathy grade II or IV&#xD;
&#xD;
          -  Severe infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Do Seon Song</last_name>
    <phone>82-31-249-8204</phone>
    <email>dsman@catholic.ac.kr</email>
  </overall_contact>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Vincent's Hospital, Korea</investigator_affiliation>
    <investigator_full_name>Do Seon Song</investigator_full_name>
    <investigator_title>Clinical assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

